Sterling, T.R., Zhao, Z., Khan, A., Chaisson, R.E., Schluger, N., Mangura B., et al. (2006) Mortality in a Large Tuberculosis Treatment Trial: Modifiable and Non-Modifiable Risk Factors. The International Journal of Tuberculosis and Lung Disease, 10, 542-549.

has been cited by the following article:

• TITLE: Clinical Response to Treatment of Central Nervous System Tuberculosis in Non-Human Immunodeficiency Virus-Infected Adolescents and Adults

  AUTHORS: Jin Young Lee, Su Jin Lee, Ji Young Park, Min Jeong Kim

  KEYWORDS: Central Nervous System Tuberculosis, Poor Response, Severity of Symptoms, Anti-Tuberculosis Drug Resistance

  JOURNAL NAME: Journal of Tuberculosis Research, Vol.4 No.4, December 7, 2016

  ABSTRACT: Introduction: More than half of patients with central nervous system tuberculosis (CNS TB) die or are left with severe neurological deficits despite receiving anti-TB treatment. Aims of the study: This study examined risk factors associated with poor response to initial treatment with four anti-TB drug regimens or three drug regimens with steroids as adjuvant therapy. Methods: This study analyzed medical records from two tertiary hospitals in Busan, Korea, between January 2009 and March 2012. The subjects were non-human immunodeficiency virus (HIV)-infected patients aged ≥16 years with clinical CNS TB. The subjects were divided into two groups according to response to treatment. Results: In totally, 52 patients with CNS TB were included. Of these, 14 (26%) and 38 (73%) showed poor and good responses, respectively. Of the patients with poor response, nine had stage III disease (64.3%) according to the British Medical Research Council (BMRC) staging system. A significantly higher proportion was seen in the good response group (p